Therapeutic Asset Ratings

8,400 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cediranib B-Cell Prolymphocytic Leukemia	City of Hope Medical Center	P1/2	B (56)
Chimeric Antigen Receptor Modified T Cells Infusion Diffuse Large B Cell Lymphoma	University of Texas Southwestern Medical Center	P1/2	B (56)
Cyclophosphamide Advanced or Metastatic Solid Tumors	Beijing Biotech	P1/2	B (56)
Cyclophosphamide Other Solid Tumors	National University Hospital, Singapore	P1/2	B (56)
DEXAMETHASONE Richter Syndrome	National Heart, Lung, and Blood Institute (NHLBI)	P1/2	B (56)
Dfn-15 Malignant Pancreatic Neoplasm	HonorHealth Research Institute	P1/2	B (56)
Epirubicin Advanced or Metastatic Solid Tumors	Hanmi Pharmaceutical Company Limited	P1/2	B (56)
Evomela Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma	City of Hope Medical Center	P1/2	B (56)
Fludarabine B-Cell Adult Acute Lymphocytic Leukemia	The First Affiliated Hospital of Soochow University	P1/2	B (56)
Fludarabine Castration-Resistant Prostate Cancer (CRPC)	Zhejiang University	P1/2	B (56)
her2bbζ/cd19t+ t cells Acute Myeloid Leukemia	David Avigan	P1/2	B (56)
Ipilimumab Colorectal Carcinoma	Incyte Corporation	P1/2	B (56)
Ipilimumab Urothelial Carcinoma	Memorial Sloan Kettering Cancer Center	P1/2	B (56)
Niraparib Fallopian Tube Carcinoma	City of Hope Medical Center	P1/2	B (56)
Pembrolizumab Advanced or Metastatic Solid Tumors	Hanmi Pharmaceutical Company Limited	P1/2	B (56)
Pembrolizumab Other Solid Tumors	Evopoint Biosciences Inc.	P1/2	B (56)
Pevonedistat Therapy-Related Acute Myeloid Leukemia	University of Southern California	P1/2	B (56)
Polyiclc Advanced Malignancies	Seqker Biosciences, Inc.	P1/2	B (56)
Romidepsin Immunodeficiencies	University of Rochester	P1/2	B (56)
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) Cancer	Bristol-Myers Squibb	P1/2	CCC (55)
[203pb]vmt01 Melanoma	Perspective Therapeutics	P1/2	CCC (55)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Myeloproliferative Neoplasm	David Wald	P1/2	CCC (55)
Antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE Cancer	LaNova Australia Pty Limited	P1/2	CCC (55)
AUTOLOGOUS CD34+ CELLS ENCODING .BETA.A-T87Q-GLOBIN GENE Transfusion-dependent Beta-Thalassemia	Editas Medicine, Inc.	P1/2	CCC (55)
Balstilimab Cancer	Agenus Inc.	P1/2	CCC (55)

Showing 201 to 225 of 8,400 assets

PreviousPage 9 of 336Next